Xenetic Biosciences, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 2.12 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.97M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company’s product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Details
| Name | Xenetic Biosciences, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 2 |
| Ceo | James Parslow |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US9840156023 |
| Cusip | 984015602 |
| Cik | 0001534525 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| James F. Parslow | Chief Financial Officer, Chief Operating Officer, Interim Chief Executive Officer and Corporate Secretary |
Contact
| Address | 945 Concord Street, Framingham, Massachusetts 01701, United States |
| Phone | 781 778 7720 |
| Website | https://www.xeneticbio.com |